Agios Pharmaceuticals (NASDAQ:AGIO): Q1 GAAP EPS of -$0.59 beats by $1.09.
Revenue of $87.1M (+188.4% Y/Y) beats by $55.51M.
https://seekingalpha.com/news/3566751-agios-pharmaceuticals-eps-beats-1_09-beats-on-revenueThursday, April 30, 2020
Abiomed EPS beats by $0.01, misses on revenue
Revenue of $206.66M (-0.2% Y/Y) misses by $2.92M.
https://seekingalpha.com/news/3566775-abiomed-eps-beats-0_01-misses-on-revenueLantheus EPS beats by $0.07, misses on revenue
Lantheus (NASDAQ:LNTH): Q1 Non-GAAP EPS of $0.36 beats by $0.07; GAAP EPS of $0.08.
Revenue of $90.7M (+4.8% Y/Y) misses by $1M.
https://seekingalpha.com/news/3566777-lantheus-eps-beats-0_07-misses-on-revenueiRadimed EPS beats by $0.05, misses on revenue
iRadimed (NASDAQ:IRMD): Q1 Non-GAAP EPS of $0.18; GAAP EPS of $0.14 beats by $0.05.
Revenue of $8.68M (+2.8% Y/Y) misses by $0.04M.
https://seekingalpha.com/news/3566781-iradimed-eps-beats-0_05-misses-on-revenuePerrigo beats Q1 consensus
Perrigo (PRGO) Q1 results:
Revenues: $1,341M (+14.2%); CSCA: $700.6M (+20.4%); CSCI: $382.7M (+9.1%); RX: $257.7M (+6.5%).
Net Income: $106.4M (+66.5%); EPS: $0.77 (+63.8%); non-GAAP Net Income: $156.7M (+7.6%); non-GAAP EPS: $1.14 (+6.5%).
CF Ops: $171.8M (+81.8%).
Due to the uncertainties associated with COVID-19
pandemic, the Company is not providing updated fiscal 2020 guidance at
this time.
Shares are down 3% premarket.
Previously: Perrigo EPS beats by $0.10, beats on revenue (April 30)
https://seekingalpha.com/news/3566800-perrigo-beats-q1-consensus
Enrollment underway in study of Mesoblast’s remestemcel-L in COVID-19
Mesoblast Limited (NASDAQ:MESO) announces the
start of enrollment in a Phase 2/3 clinical trial evaluating allogeneic
mesenchymal stem cell candidate remestemcel-L in COVID-19 patients with
moderate-to-severe acute respiratory distress syndrome.
Enrollment of up to 300 ventilator-dependent
patients should wind up in three-to-four months. The primary endpoint is
all-cause mortality within 30 days of randomization. A key secondary
endpoint is the number of days off mechanical ventilator support.
https://seekingalpha.com/news/3566832-enrollment-underway-in-study-of-mesoblasts-remestemcel-l-in-covidminus-19
WuXi teams up with Aravive to develop biologics for cancer
WuXi Biologics (OTCPK:WXXWY) inks an agreement with Aravive (NASDAQ:ARAV) aimed at developing high-affinity bispecific antibodies for a target in cancer and fibrosis called CCN2.
Under the terms of the partnership, Aravive will
have access to the former’s WuXiBody platform and will be responsible
for preclinical and clinical development while WuXi will be responsible
for discovery, process development and manufacturing.
Financial terms remain confidential.
https://seekingalpha.com/news/3566839-wuxi-teams-up-aravive-to-develop-biologics-for-cancer
Subscribe to:
Posts (Atom)